Emibetuzumab, previously known as LY2875358, represents a novel treatment strategy in oncology, specifically targeting the HGF Receptor tyrosine protein. This recombinant antibody functions by specifically attaching to https://bookmark-template.com/story29339877/emibetuzumab-a-deep-investigation-into-the-ly2875358-anti-hepatocyte-growth-factor-receptor-antibody